326 related articles for article (PubMed ID: 29433939)
1. Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency.
Prieve MG; Harvie P; Monahan SD; Roy D; Li AG; Blevins TL; Paschal AE; Waldheim M; Bell EC; Galperin A; Ella-Menye JR; Houston ME
Mol Ther; 2018 Mar; 26(3):801-813. PubMed ID: 29433939
[TBL] [Abstract][Full Text] [Related]
2. An Exon-Specific Small Nuclear U1 RNA (ExSpeU1) Improves Hepatic OTC Expression in a Splicing-Defective
Balestra D; Ferrarese M; Lombardi S; Ziliotto N; Branchini A; Petersen N; Bosma P; Pinotti M; van de Graaf SFJ
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33228018
[No Abstract] [Full Text] [Related]
3. Induction and prevention of severe hyperammonemia in the spfash mouse model of ornithine transcarbamylase deficiency using shRNA and rAAV-mediated gene delivery.
Cunningham SC; Kok CY; Dane AP; Carpenter K; Kizana E; Kuchel PW; Alexander IE
Mol Ther; 2011 May; 19(5):854-9. PubMed ID: 21386824
[TBL] [Abstract][Full Text] [Related]
4. Humanized liver mouse model with transplanted human hepatocytes from patients with ornithine transcarbamylase deficiency.
Sugahara G; Yamasaki C; Yanagi A; Furukawa S; Ogawa Y; Fukuda A; Enosawa S; Umezawa A; Ishida Y; Tateno C
J Inherit Metab Dis; 2021 May; 44(3):618-628. PubMed ID: 33336822
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive characterization of ureagenesis in the spf
Allegri G; Deplazes S; Rimann N; Causton B; Scherer T; Leff JW; Diez-Fernandez C; Klimovskaia A; Fingerhut R; Krijt J; Kožich V; Nuoffer JM; Grisch-Chan HM; Thöny B; Häberle J
J Inherit Metab Dis; 2019 Nov; 42(6):1064-1076. PubMed ID: 30714172
[TBL] [Abstract][Full Text] [Related]
6. Corticosteroid suppresses urea-cycle-related gene expressions in ornithine transcarbamylase deficiency.
Imoto K; Tanaka M; Goya T; Aoyagi T; Takahashi M; Kurokawa M; Tashiro S; Kato M; Kohjima M; Ogawa Y
BMC Gastroenterol; 2022 Mar; 22(1):144. PubMed ID: 35346058
[TBL] [Abstract][Full Text] [Related]
7. A new mouse model of mild ornithine transcarbamylase deficiency (spf-j) displays cerebral amino acid perturbations at baseline and upon systemic immune activation.
Tarasenko TN; Rosas OR; Singh LN; Kristaponis K; Vernon H; McGuire PJ
PLoS One; 2015; 10(2):e0116594. PubMed ID: 25647322
[TBL] [Abstract][Full Text] [Related]
8. AAV2/8-mediated correction of OTC deficiency is robust in adult but not neonatal Spf(ash) mice.
Cunningham SC; Spinoulas A; Carpenter KH; Wilcken B; Kuchel PW; Alexander IE
Mol Ther; 2009 Aug; 17(8):1340-6. PubMed ID: 19384294
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of a clinical candidate AAV8 vector for ornithine transcarbamylase (OTC) deficiency reveals functional enzyme from each persisting vector genome.
Wang L; Morizono H; Lin J; Bell P; Jones D; McMenamin D; Yu H; Batshaw ML; Wilson JM
Mol Genet Metab; 2012 Feb; 105(2):203-11. PubMed ID: 22133298
[TBL] [Abstract][Full Text] [Related]
10. AAV-encoded OTC activity persisting to adulthood following delivery to newborn spf(ash) mice is insufficient to prevent shRNA-induced hyperammonaemia.
Cunningham SC; Kok CY; Spinoulas A; Carpenter KH; Alexander IE
Gene Ther; 2013 Dec; 20(12):1184-7. PubMed ID: 24108150
[TBL] [Abstract][Full Text] [Related]
11. Correction of ornithine transcarbamylase deficiency in adult spf(ash) mice and in OTC-deficient human hepatocytes with recombinant adenoviruses bearing the CAG promoter.
Kiwaki K; Kanegae Y; Saito I; Komaki S; Nakamura K; Miyazaki JI; Endo F; Matsuda I
Hum Gene Ther; 1996 May; 7(7):821-30. PubMed ID: 8860834
[TBL] [Abstract][Full Text] [Related]
12. Sustained correction of OTC deficiency in spf( ash) mice using optimized self-complementary AAV2/8 vectors.
Wang L; Wang H; Morizono H; Bell P; Jones D; Lin J; McMenamin D; Yu H; Batshaw ML; Wilson JM
Gene Ther; 2012 Apr; 19(4):404-10. PubMed ID: 21850052
[TBL] [Abstract][Full Text] [Related]
13. Long-term correction of ammonia metabolism and prolonged survival in ornithine transcarbamylase-deficient mice following liver-directed treatment with adeno-associated viral vectors.
Moscioni D; Morizono H; McCarter RJ; Stern A; Cabrera-Luque J; Hoang A; Sanmiguel J; Wu D; Bell P; Gao GP; Raper SE; Wilson JM; Batshaw ML
Mol Ther; 2006 Jul; 14(1):25-33. PubMed ID: 16677864
[TBL] [Abstract][Full Text] [Related]
14. Interaction between murine spf-ash mutation and genetic background yields different metabolic phenotypes.
Marini JC; Erez A; Castillo L; Lee B
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1764-71. PubMed ID: 17925451
[TBL] [Abstract][Full Text] [Related]
15. Early intervention for late-onset ornithine transcarbamylase deficiency.
Fujisawa D; Mitsubuchi H; Matsumoto S; Iwai M; Nakamura K; Hoshide R; Harada N; Yoshino M; Endo F
Pediatr Int; 2015; 57(1):e1-3. PubMed ID: 25711267
[TBL] [Abstract][Full Text] [Related]
16. Lipid nanoparticle-targeted mRNA formulation as a treatment for ornithine-transcarbamylase deficiency model mice.
Yamazaki K; Kubara K; Ishii S; Kondo K; Suzuki Y; Miyazaki T; Mitsuhashi K; Ito M; Tsukahara K
Mol Ther Nucleic Acids; 2023 Sep; 33():210-226. PubMed ID: 37520683
[TBL] [Abstract][Full Text] [Related]
17. Efficient mitochondrial import of newly synthesized ornithine transcarbamylase (OTC) and correction of secondary metabolic alterations in spf(ash) mice following gene therapy of OTC deficiency.
Zimmer KP; Bendiks M; Mori M; Kominami E; Robinson MB; Ye X; Wilson JM
Mol Med; 1999 Apr; 5(4):244-53. PubMed ID: 10448647
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency.
Raper SE; Yudkoff M; Chirmule N; Gao GP; Nunes F; Haskal ZJ; Furth EE; Propert KJ; Robinson MB; Magosin S; Simoes H; Speicher L; Hughes J; Tazelaar J; Wivel NA; Wilson JM; Batshaw ML
Hum Gene Ther; 2002 Jan; 13(1):163-75. PubMed ID: 11779420
[TBL] [Abstract][Full Text] [Related]
19. A mutation-independent CRISPR-Cas9-mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency.
Wang L; Yang Y; Breton C; Bell P; Li M; Zhang J; Che Y; Saveliev A; He Z; White J; Latshaw C; Xu C; McMenamin D; Yu H; Morizono H; Batshaw ML; Wilson JM
Sci Adv; 2020 Feb; 6(7):eaax5701. PubMed ID: 32095520
[TBL] [Abstract][Full Text] [Related]
20. AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice.
Wang L; Bell P; Morizono H; He Z; Pumbo E; Yu H; White J; Batshaw ML; Wilson JM
Mol Genet Metab; 2017 Apr; 120(4):299-305. PubMed ID: 28283349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
